<div id="readability-page-1"><p><span>Beam Therapeutics (NASDAQ:BEAM - Get Free Report)</span> was upgraded by Bank of America from a &#34;neutral&#34; rating to a &#34;buy&#34; rating in a research report issued to clients and investors on Friday,Briefing.com Automated Import reports. The brokerage presently has a $42.00 price objective on the stock. Bank of America's price target indicates a potential upside of 89.27% from the company's current price.</p><div><p><span></span><span>Get <strong>Beam Therapeutics</strong> alerts:</span></p></div><ul><li>MarketBeat Week in Review – 3/4 – 3/8</li></ul><p>A number of other equities research analysts have also weighed in on the stock. Royal Bank of Canada lifted their target price on shares of Beam Therapeutics from $24.00 to $26.00 and gave the company a &#34;sector perform&#34; rating in a research note on Wednesday, February 26th. Guggenheim  restated a &#34;buy&#34; rating and issued a $78.00 price objective on shares of Beam Therapeutics in a report on Thursday, February 27th. Wedbush  reaffirmed an &#34;outperform&#34; rating and set a $57.00 price target on shares of Beam Therapeutics in a report on Monday, March 10th. Scotiabank raised Beam Therapeutics from a &#34;sector perform&#34; rating to a &#34;sector outperform&#34; rating and set a $40.00 target price on the stock in a report on Monday, March 10th. Finally, Cantor Fitzgerald  restated an &#34;overweight&#34; rating on shares of Beam Therapeutics in a research note on Wednesday, March 12th. Two analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued  a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of &#34;Buy&#34; and a consensus target price of $49.45.</p><p><b>Get Our Latest Stock Analysis on BEAM</b></p><h2>Beam Therapeutics Trading Up 1.3 %</h2><ul><li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li></ul><p>NASDAQ:BEAM opened at $22.19 on Friday. The stock has a market capitalization of $2.21 billion, a PE ratio of -12.61 and a beta of 1.91. The firm's 50 day moving average is $26.67 and its 200 day moving average is $25.87. Beam Therapeutics has a 12 month low of $20.84 and a 12 month high of $35.25. </p><p>Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($1.09) EPS for the quarter, topping the consensus estimate of ($1.25) by $0.16. The business had revenue of $30.00 million during the quarter, compared to the consensus estimate of $16.47 million. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The firm's revenue was down 90.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.73 EPS.  Research analysts predict that  Beam Therapeutics will post -4.57 earnings per share for the current year. </p><h2>Insider Activity at Beam Therapeutics</h2><ul><li>Is CRISPR Therapeutics the NVIDIA of gene editing?</li></ul><p>In other news, CEO John M. Evans sold 30,000 shares of Beam Therapeutics stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $26.75, for a total value of $802,500.00. Following the sale, the chief executive officer now owns 908,659 shares of the company's stock, valued at $24,306,628.25. The trade was a 3.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, insider Christine Bellon sold 1,241 shares of Beam Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total value of $30,627.88. Following the completion of the sale, the insider now owns 102,968 shares in the company, valued at approximately $2,541,250.24. This trade represents a 1.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own  4.20% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Institutional investors have recently added to or reduced their stakes in the company. Wealthfront Advisers LLC purchased a new stake in shares of  Beam Therapeutics during the 4th quarter valued at $41,000.  GF Fund Management CO. LTD. purchased a new position in shares of  Beam Therapeutics in the 4th quarter valued at $43,000.  Sterling Capital Management LLC raised its stake in shares of  Beam Therapeutics by 816.0% in the 4th quarter. Sterling Capital Management LLC now owns 2,409 shares of the company's stock valued at $60,000 after acquiring an additional 2,146 shares during the period.  KBC Group NV lifted its holdings in shares of  Beam Therapeutics by 103.2% during the 4th quarter. KBC Group NV now owns 4,143 shares of the company's stock valued at $103,000 after acquiring an additional 2,104 shares in the last quarter.  Finally, Blue Trust Inc. boosted its position in  Beam Therapeutics by 36.3% during the 4th quarter. Blue Trust Inc. now owns 4,274 shares of the company's stock worth $105,000 after purchasing an additional 1,139 shares during the period. Institutional investors and hedge funds own  99.68% of the company's stock. </p><h2>Beam Therapeutics Company Profile</h2> (Get Free Report)<p>Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Beam Therapeutics</li><li>Investing In Preferred Stock vs. Common Stock</li><li>3 Momentum Stocks Near 52-Week Highs to Watch for More Growth</li><li>Business Services Stocks Investing</li><li>Microsoft’s Big Malaysia Bet Could Pay Off for Investors</li><li>What Are Some of the Best Large-Cap Stocks to Buy?</li><li>The 5 Most Oversold Stocks on the Market Are… </li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkVBTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkVBTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Beam Therapeutics Right Now?</h2><p>Before you consider Beam Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beam Therapeutics wasn't on the list.</p><p>While Beam Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

BEAM

<p>Bank of America upgraded Beam Therapeutics (NASDAQ:BEAM) from a "neutral" to a "buy" rating, setting a target price of $42.00, indicating a potential upside of 89.27%. Other analysts have also raised their target prices, with a consensus rating of "Buy" and an average target of $49.45. Beam Therapeutics reported a quarterly EPS of ($1.09), exceeding estimates, with revenue of $30 million. The stock opened at $22.19, with a market cap of $2.21 billion. Insider trading activity included CEO John M. Evans selling 30,000 shares.</p>

Beam Therapeutics (NASDAQ:BEAM) Raised to Buy at Bank of America